Neutra Corp. (NTRR) announced plans today to forge ahead with the marketing and development of a new inhaler containing an all-natural, libido-boosting supplement as an alternative to populartestosterone drugs the FDA says increase the risk of heart attack and stroke.
A CBS outlet reported last week that nearly three percent of men over 40 take testosterone drugs for low energy and libido, fueling a $2 billion market in the U.S. But the FDA issued a statement last week saying that overuse of testosterone drugs is unsafe for those with age-related diseases, and are not to be used to counteract the normal effects of aging. NTRR is working to develop a novel new alternative to testosterone drugs that uses an all-natural and effective herbal supplement, eliminating the risks and barriers associated with prescriptions.
“Testosterone boosters, which are intended to be used only by a select group of men diagnosed with low testosterone by their doctors, are a risky and often ineffective solution to the loss of libido,” said NTRR CEO Chris Brown. “We’re now seeking development partners for a cutting-edge new inhaler that will boost libido quickly, naturally and inconspicuously, without the risk factors described by the FDA in testosterone drugs.”
As vapor pens and e-cigs become a lifestyle accessory around the globe, NTRR believes that disposable inhaler technology is poised to become a new and better industry standard for a wide variety of supplements and nutraceuticals—including those developed to improve sexual function and desire in men. The company’s research indicates that a libido-boosting inhaler will be more effective and faster-acting than pills and other supplements on the market, and NTRR plans to be the first to offer such a product.
The new technology is one of several products that the company is developing to diversify its offerings and expand its earnings potential in the global nutraceuticals market.
About Neutra Corp.
Neutra Corp. is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products. By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (GWPRF), INSYS Therapeutics, Inc. (INSY) and ENDEXX Corp. (EDXC), delivering technological advancements in the cultivation and processing of cannabis in approved markets. For investing information and performance data, please visit www.neutracorp.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Chris Brown, 813-367-2041
President and CEO
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com